U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
U.S. Stock Futures Slip as Markets Brace for Big Tech Earnings and Key Data 
DOJ Sues Virginia Over Failure to Provide Full Voter Registration Records 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Gold, Silver, and Platinum Rally as Precious Metals Recover from Sharp Selloff 
Federal Judge Blocks Trump Administration Move to End TPS for Haitian Immigrants 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
China and Uruguay Strengthen Strategic Partnership Amid Shifting Global Order 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Japan Finance Minister Defends PM Takaichi’s Remarks on Weak Yen Benefits 
RBA Raises Interest Rates by 25 Basis Points as Inflation Pressures Persist 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Bristol Myers Squibb has sued AstraZeneca for its antibody-based cancer treatment Imjudo, which it says infringes its patents for its drug Yervoy
According to Bristol Myer, Imjudo fights cancer in the same way as Yervoy.
Bristol Myers has previously sued AstraZeneca for patent infringement over the latter’s other cancer drug, Imfinzi.
AstraZeneca said it is aware of the complaint and will respond to it "at the appropriate time."
The FDA has also approved the immunotherapy Yervoy for the treatment of kidney, lung, colorectal, and other cancers. The FDA initially approved Yervoy in 2011 to treat melanoma.
In 2021, Bristol Myers sold over $2 billion worth of Yervoy.
AstraZeneca’s Imjudo was given FDA approval last year to be used in conjunction with Imfinzi to treat liver and lung cancer.
In the second lawsuit, Bristol Myers claimed that AstraZeneca had violated two patents on the use of antibodies to treat cancer and strengthen a patient's immune system.
Bristol Myers insists that AstraZeneca was aware of the patents, being on notice due to licensing discussions and the Imfinzi lawsuit.
The lawsuit seeks an unspecified amount of money for damages.
